Dose-finding approach for dose escalation with overdose control considering incomplete observations

Statistics in Medicine

Volumn 30, Issue 13, 2011, Pages 1584-1594

  Mauguen, A ^a   Le Deley, M C ^a   Zohar, S ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Dose finding study; Escalation with overdose control; Phase I trial; Time to event; Trial duration

Indexed keywords

ARTICLE; CALCULATION; CONTROLLED STUDY; DOSE RESPONSE; ESCALATION WITH OVERDOSE CONTROL METHOD; HUMAN; INTERMETHOD COMPARISON; MAXIMUM TOLERATED DOSE; METHODOLOGY; PROBABILITY; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; TIME TO EVENT DOSE ESCALATION METHOD WITH OVERDOSE CONTROL;

CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; OVERDOSE;

EID: 79956107922     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4128     Document Type: Article

References (12)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46(1):33-48.
2. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1998; 17(10):1103-1120.
3. Tighiouart M, Rogatko A, Babb JS. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Statistics in Medicine 2005; 24(14):2183-2196.
4. Chu P, Lin Y, Shih W. Unifying CRM and EWOC designs for phase I cancer clinical trials. Journal of Statistical Planning and Inference 2009; 139(3):1146-1163.
5. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56(4):1177-1182.
6. Braun TM. Generalizing the TITE-CRM to adapt for early-and late-onset toxicities. Statistics in Medicine 2006; 25(12):2071-2083.
7. Barrett JS, Skolnik J, Jayaraman B, Patel D, Adamson P. Improving study design and conduct efficiency of event-driven clinical trials via Discrete Event Simulation: application to pediatric oncology. [Poster ] Sixteenth Meeting of the Population Approach Group in Europe, Kobenhavn, Denmark, 13-15 June 2007.
8. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
9. Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in Medicine 2001; 20:2079-2090.
10. Muler J, McGinn C, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski M. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. Journal of Clinical Oncology 2004; 22(2):238-243.
11. Mackler N, Dunn R, Hellerstedt B, Cooney K, Fardig J, Olson K, Pienta K, Smith D. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer 2006; 106(12):2617-2623.
12. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK et al. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. Journal of Clinical Oncology 2004; 22(4):602-609.